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Abstract The purpose of the study was to evaluate the
efficacy and safety of wet chamber warming goggles
(Blephasteam) in patients with meibomian gland
dysfunction (MGD) unresponsive to warm compress
treatment. We consecutively enrolled 50 adult patients
with low-delivery, non-cicatricial, MGD, and we
instructed them to apply warm compresses twice a day
for 10 min for 3 weeks and to use Blephasteam
(Laboratoires Thea, Clermont-Ferrand, France) twice a
day for 10 min for the following 3 weeks. We consid-
ered ‘‘not-responders’’ to warm compress treatment the
patients who showed no clinically significant Ocular
Surface Disease Index (OSDI) improvement after the
first 3 weeks. Clinical and in vivo confocal outcome
measures were assessed in the worst eye (lower BUT) at
baseline, after 3 weeks, and after 6 weeks. Eighteen/50
patients were not-responders to warm compress treat-
ment. These patients, after 3 weeks of treatment with
Blephasteam, showed significant improvement of
OSDI score (36.4 ± 15.8 vs 20.2 ± 12.4; P \ 0.05,
paired samples t test), increased BUT (3.4 ± 1.6 vs
7.6 ± 2.7; P \ 0.05), and decreased acinar diameter and
area (98.4 ± 18.6 vs 64.5 ± 14.4 and 8,037 ± 1,411 vs
5,532 ± 1,172, respectively; P \ 0.05). Neither warm
compresses nor Blephasteam determined adverse
responses. In conclusion, eyelid warming is the mainstay
of the clinical treatment of MGD and its poor results may
be often due to lack of compliance and standardization.
Blephasteam wet chamber warming goggles are a
promising alternative to classical warm compress treat-
ment, potentially able to improve the effectiveness of the
‘‘warming approach.’’
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Introduction
Meibomian gland dysfunction (MGD) is a common
chronic condition, affecting the tear film and the
ocular surface and causing symptoms of eye irritation
[1, 2].
Meibomian gland obstruction, due to either termi-
nal duct obstruction or altered secretion, is the most
common form of MGD [2]. Eyelid warming, usually
achieved with simple warm compresses, is regarded as
the mainstay of the clinical treatment of this condition,
but its efficacy is affected by lack of standardization,
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in terms of duration and maintenance of temperature,
and by a scarce compliance [3]. In the last few years,
different devices have been developed in order to try to
improve the heat therapy efficacy [3–8].
In vivo laser scanning confocal microscopy
(LSCM) is an emerging technology to study the ocular
surface in several conditions, including dry eye and
MGD [9–11]. At present, LSCM is showing promising
clinical applications [9] and recent studies reported its
helpfulness in detecting ocular surface response to
treatment [12–14].
The aim of this research is to evaluate the safety and
efficacy of Blephasteam (Laboratoires Thea, Cler-
mont-Ferrand, France) eyelid-warming device in the
management of MGD unresponsive to warm compress
treatment and to study treatment-related clinical and
confocal changes.
Methods
We consecutively studied 50 adult patients with mild
to moderate low-delivery, non-cicatricial, MGD.
Written informed consent was obtained from all
subjects before enrollment, and this study adhered to
the tenets of the declaration of Helsinki. MGD
classification and grading were performed according
to the 2011 International Workshop on MGD [2, 15].
Briefly, we included patients with symptoms of ocular
discomfort (Ocular Surface Disease Index—OSDI—
score[12) [16], tear fluorescein break-up time (BUT)
\5, mild to moderate meibum quality abnormality
(score 11–20, according to Bron’ Scale) [17, 18], and
mild to moderate expressibility reduction [15]. Exclu-
sion criteria included blepharitis, ocular allergies,
contact lens wear, hyposecretive dry eye, history of
ocular trauma or surgery, cicatricial ocular surface
diseases, and systemic or topical therapies (tear
substitutes excepted) that would interfere with tear
film and ocular surface.
All these patients were instructed to perform warm
compress treatment twice a day for 10 min.
After 3 weeks of treatment, we defined as ‘‘not-
responders to warm compress treatment’’ patients who
did not show clinically significant OSDI improve-
ment, based on the previously validated OSDI mini-
mal clinically important difference [19].
Both ‘‘responder’’ and ‘‘not-responder’’ patients
were then instructed to use Blephasteam (Laboratoires
Thea, Clermont-Ferrand, France) twice a day for
10 min, following the manufacturer instructions, for
the following 3 weeks.
All the visits (screening and enrollment—V0, visit at
day 21 ± 2—V1, and visit at day 42 ± 2—V2)
included the same procedures, performed in the order
suggested by the 2007 International Dry Eye Workshop
[20]: OSDI questionnaire, fluorescein BUT, fluorescein
corneal staining (quantified using the CLEK scheme)
[21], Schirmer test without topical anesthesia, meibo-
mian gland expression, and LSCM (HRT II Corneal
Rostock Module, Heidelberg Engineering GmbH,
Dossenheim, Germany) of meibomian glands. Confo-
cal examination was performed at the lower eyelid
margin, following a previously published procedure
[22–24]. Meibomian acinar units were analyzed, quan-
tifying their density, mean diameter, and area.
No changes in the concomitant medications,
including artificial tears, were allowed during the
study period.
The outcome measures were assessed in the worst
eye, defined as the eye with the lower BUT.
Statistical analysis
The statistical analysis was conducted with commercial
software (SPSS for Windows, ver. 12.0; SPSS,
Chicago, IL, USA). The comparisons between consec-
utive visits were performed using the t test for repeated
measures for parametric variables and with the Wilco-
xon test for non-parametric variables. The comparisons
between ‘‘responders’’ and ‘‘not-responders’’ to warm
compress treatment were done using the t test for
independent samples for parametric variables and the
Mann–Whitney U test for non-parametric variables.
The minimum criterion for tests of significance was
P \ 0.01.
Results
The 50 enrolled patients (31 females and 19 males)
had a mean age of 64 ± 12 years.
After 3 weeks of warm compress treatment, 18
patients (36 %) were classified as ‘‘not-responders’’
and 32 (64 %) as ‘‘responders.’’
No significant differences were found between the
baseline characteristics of ‘‘responders’’ and ‘‘not-
responders.’’
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Neither warm compresses nor Blephasteam
caused adverse events or problems of tolerability in
our patients.
In the ‘‘not-responders’’ group, comparing V0 to
V1, we found no significant treatment-related (warm
compresses) improvement in clinical findings. Fur-
thermore, in this same group, we observed significant
improvement of OSDI score (Table 1), increase of
BUT (Table 2), and decrease of both acinar mean
diameter (Table 3) and area (Table 4) (Fig. 1) from
V1 to V2.
Fluorescein staining, meibomian gland expressibil-
ity, and meibum quality showed no significant differ-
ences during the follow-up (Wilcoxon test).
Discussion
MGD, specifically in the low-delivery, non-cicatricial
form, is an increasingly prevalent affliction/with
potentially severe detriments to well-being [1]. Ded-
icated and reliable methods to monitor and effective
approaches to manage the disease are still partially
unmet needs. LSCM offers new opportunities to
perform in vivo, non-invasive examinations of mei-
bomian glands. This technology has proven to have the
potential to diagnose MGD with high sensitivity and
specificity [25] and to explore the different patterns of
the disease, providing new information on the path-
ogenetic process and the acinar morphological
Table 1 OSDI score during follow-up, patients responders to and not-responders to warm compress treatment
V0 V1 V2 *P (V0 vs V1) *P (V1 vs V2)
Responders (n = 32) 36.3 ± 17.1 22.7 ± 13.1 20.5 ± 14.2 \0.05 n.s.
Not-responders (n = 18) 38.2 ± 15.5 36.4 ± 15.8 20.2 ± 12.4 n.s. \0.05
**P n.s. \0.05 n.s.
n.s. Not significant
* P by t test for repeated measures
** P by t test for independent samples
Table 2 BUT (seconds) during follow-up, patients responders to and not-responders to warm compress treatment
V0 V1 V2 *P (V0 vs V1) *P (V1 vs V2)
Responders (n = 32) 3.3 ± 1.8 6.7 ± 2.1 7.2 ± 2.2 \0.05 n.s.
Not-responders (n = 18) 3.8 ± 1.4 3.4 ± 1.6 7.6 ± 2.7 n.s. \0.05
**P n.s. \0.05 n.s.
n.s. Not significant
* P by t test for repeated measures
** P by t test for independent samples
Table 3 LSCM assessment of mean acinar diameter (lm) during follow-up, patients responders to and not-responders to warm
compress treatment
V0 V1 V2 *P (V0 vs V1) *P (V1 vs V2)
Responders (n = 32) 108.3 ± 19.4 84.2 ± 17.6 77.5 ± 18.0 \0.05 n.s.
Not-responders (n = 18) 104.8 ± 15.1 98.4 ± 18.6 64.5 ± 14.4 n.s. \0.05
**P n.s. \0.05 n.s.
n.s. Not significant
* P by t test for repeated measures
** P by t test for independent samples
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changes [22–24]. Moreover, the previously hypothe-
sized [12] suitability of LSCM to detect and quantify
the MGD response to treatment may be confirmed by
the present study. Our results showed agreement
between clinical (symptoms and BUT) and confocal
changes, in the absence of significant variations of
traditional meibomian expression scores. These inter-
esting data suggest the need for future studies to
compare confocal and clinical examination of meibo-
mian glands and to confirm the utility of incorporating
LSCM analysis in the assessment of patient response
to therapy.
Our study confirms the usefulness of the well-
known and broadly accepted [3] eyelid-warming
approach to MGD, but it also highlights that this
treatment may be ineffective in 1/3 of the patients,
although carefully selected. The good clinical and
morphological response to Blephasteam of subjects
‘‘not-responder’’ to warm compress treatment sug-
gests that ineffectiveness may be due to poor stan-
dardization and compliance more than to poor
rationale. Medical devices dedicated to eyelid warm-
ing try to bridge this gap in the management of MGD
patients. Blephasteam is an electrical pair of goggles
that provides warmth and steam, with controlled
treatment temperature and duration. Previous studies
in healthy volunteers [7, 8] already showed that this
device, compared to traditional warm compresses,
provides longer warming of the eyelid margin without
any adverse ocular response. Our results show its
safety and efficacy in MGD patients and its potential
superiority to warm compress treatment in ideal
candidates to warming therapy.
In conclusion, new technologies as LSCM and
eyelid-warming devices promise to play an important
role in the management of MGD, improving the
effectiveness of non-pharmacological treatment of
this common condition.
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Table 4 LSCM assessment of mean acinar area (lm2) during follow-up, patients responders to and not-responders to warm
compress treatment
V0 V1 V2 *P (V0 vs V1) *P (V1 vs V2)
Responders (n = 32) 8,645 ± 1,980 6,026 ± 1,883 5,879 ± 1,820 \0.05 n.s.
Not-responders (n = 18) 8,276 ± 1,691 8,037 ± 1,411 5,532 ± 1,172 n.s. \0.05
**P n.s. \0.05 n.s.
n.s. Not significant
* P by t test for repeated measures
** P by t test for independent samples
Fig. 1 LSCM images of meibomian glands’ acinar units in a patient not-responder to warm compress treatment: baseline (a),
V1—after 3 weeks of warm compresses (b), and V2—after 3 weeks of treatment with Blephasteam(c)
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